A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

PURPOSE: To estimate the maximum tolerated dose (MTD) and/or identify the recommended Phase II dose (RP2D) for combined INC280 and buparlisib in patients with recurrent glioblastoma with homozygous phosphatase and tensin homolog (PTEN) deletion, mutation or protein loss. METHODS: This multicenter, o...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Neurooncol
Huvudupphovsmän: van den Bent, Martin, Azaro, Analia, De Vos, Filip, Sepulveda, Juan, Yung, W. K. Alfred, Wen, Patrick Y., Lassman, Andrew B., Joerger, Markus, Tabatabai, Ghazaleh, Rodon, Jordi, Tiedt, Ralph, Zhao, Sylvia, Kirsilae, Tiina, Cheng, Yi, Vicente, Sergio, Balbin, O. Alejandro, Zhang, Hefei, Wick, Wolfgang
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer US 2019
Ämnen:
Clinical Study
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6938467/
https://ncbi.nlm.nih.gov/pubmed/31776899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-019-03337-2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk